➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
McKinsey
AstraZeneca
Mallinckrodt
McKesson

Last Updated: October 23, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,415,008

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,415,008
Title:Dry powder inhaler
Abstract: This invention provides a dry powder inhaler comprising: a dry powder medicament comprising fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of fluticasone propionate per actuation is less than 100 .mu.g; and wherein the dose provides a baseline-adjusted FEV.sub.1 in a patient of more than 150 mL within 30 minutes of receiving the dose. A method of treating a patient includes administering to a patient a dry powder medicament having fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of fluticasone propionate per actuation is less than 100 .mu.g; and wherein the dose provides a baseline-adjusted FEV.sub.1 in a patient of more than 150 mL within 30 minutes of receiving the dose.
Inventor(s): Dalvi; Mukul (Weston, FL), Tee; Seah Kee (Weston, FL)
Assignee: Teva Branded Pharmaceutical Products R&D, Inc. (Frazer, PA)
Application Number:15/001,853
Patent Claims: 1. A dry powder inhaler comprising: a dry powder medicament comprising fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of fluticasone propionate per actuation is less than 100 .mu.g; and wherein the dose provides a baseline-adjusted FEV.sub.1 in a patient of more than 150 mL within 30 minutes of receiving the dose.

2. The inhaler as claimed in claim 1, wherein the baseline-adjusted FEV.sub.1 remains above 150 mL for at least 6 hours after receiving the dose.

3. The inhaler as claimed in claim 1, wherein the dose of fluticasone propionate is less than 75 .mu.g.

4. The inhaler as claimed in claim 3, wherein the doses of fluticasone propionate/salmeterol in .mu.g are 50/12.75 or 25/12.75 per actuation.

5. The inhaler as claimed in claim 1, wherein the particle size of the fluticasone propionate is d10=0.4-1.1 .mu.m, d50=11.1-3.0 .mu.m, d90=2.6-7.5 .mu.m and NLT95%<10 .mu.m, measured by laser diffraction as an aqueous dispersion.

6. The inhaler as claimed in claim 1, wherein the particle size of the salmeterol xinafoate is dl 0=0.4-1.3 .mu.m, d50=1.4-3.0 .mu.m, d90=2.4-6.5 .mu.m and NLT95%<10 .mu.m, measured by laser diffraction as an aqueous dispersion.

7. The inhaler as claimed in claim 1, wherein the lactose carrier is comprised of a coarse lactose and fine lactose, wherein the fine lactose is defined by a particle size of <10 .mu.m, measured by laser diffraction as a dispersion in air.

8. The inhaler as claimed in claim 7, wherein the lactose carrier contains 1-10 wt % of fine lactose.

9. The inhaler as claimed in claim 1, wherein the lactose particle size is d10=15-50 .mu.m, d50=80-120 .mu.m, d90=120-200 .mu.m.

10. The inhaler as claimed in claim 1, wherein the inhaler comprises a cyclone deagglomerator for breaking up agglomerates of the dry powder.

11. The inhaler as claimed in claim 10, wherein the deagglomerator comprises: an inner wall defining a swirl chamber extending along an axis from a first end to a second end; a dry powder supply port in the first end of the swirl chamber for providing fluid communication between a dry powder delivery passageway of the inhaler and the first end of the swirl chamber; at least one inlet port in the inner wall of the swirl chamber adjacent to the first end of the swirl chamber providing fluid communication between a region exterior to the deagglomerator and the first end of the swirl chamber; an outlet port providing fluid communication between the second end of the swirl chamber and a region exterior to the deagglomerator; and vanes at the first end of the swirl chamber extending at least in part radially outwardly from the axis of the chamber, each of the vanes having an oblique surface facing at least in part in a direction transverse to the axis; whereby a breath induced low pressure at the outlet port causes air flows into the swirl chamber through the dry powder supply port and the inlet port.

12. The inhaler as claimed in claim 1, wherein the inhaler comprises a reservoir for containing the medicament and an arrangement for delivering a metered dose of the medicament from the reservoir.

13. The inhaler as claimed in claim 1, wherein the inhaler comprises a delivery passageway for directing an inhalation-induced air flow through a mouthpiece and a channel extending from the delivery passageway to the medicament.

14. The inhaler as claimed in claim 1, comprising: a sealed reservoir including a dispensing port; a channel communicating with the dispensing port and including a pressure relief port; a conduit providing fluid communication between an interior of the sealed reservoir and the pressure relief port of the channel; and a cup assembly movably received in the channel and including, a recess adapted to receive medicament when aligned with the dispensing port, a first sealing surface adapted to seal the dispensing port when the recess is unaligned with the dispensing port, and a second sealing surface adapted to sealing the pressure relief port when the recess is aligned with the dispensing port and unseal the pressure relief port when the recess is unaligned with the dispensing port.

15. The inhaler as claimed in claim 1 for the treatment of asthma or COPD.

16. The inhaler as claimed in claim 3, wherein the dose of fluticasone propionate/salmeterol in .mu.g is 49/12.75 per actuation.

17. A method for the treatment of asthma or allergic rhinitis or COPD comprising administering to a patient a dry powder medicament comprising fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of fluticasone propionate per actuation is less than 100 .mu.g; and wherein the dose provides a baseline-adjusted FEV.sub.1 in a patient of more than 150 mL within 30 minutes of receiving the dose.

18. The method as claimed in claim 17, wherein the dose of fluticasone propionate is less than 75 .mu.g.

19. The method as claimed in claim 17, wherein the doses of fluticasone propionate/salmeterol in .mu.g are 50/12.75 or 25/12.75 per actuation.

20. The method as claimed in claim 17, wherein the dose of fluticasone propionate/salmeterol in .mu.g is 49/12.75 per actuation.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Express Scripts
Baxter
McKesson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.